Literature DB >> 26261732

Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome.

Abhasnee Sobhonslidsuk1.   

Abstract

Spontaneous bacterial peritonitis (SBP), refractory ascites, hepatorenal syndrome (HRS), hyponatremia and hepatic encephalopathy are complications which frequently happen during a clinical course of decompensated cirrhosis. Splanchnic and peripheral vasodilatation, increased intrarenal vasoconstriction and impaired cardiac responsive function are pathological changes causing systemic and hemodynamic derangement. Extreme renal vasoconstriction leads to severe reduction of renal blood flow and glomerular filtration rate, which finally evolves into the clinical feature of HRS. Clinical manifestations of type 1 and type 2 HRS come to medical attention differently. Patients with type 1 HRS present as acute kidney injury whereas those with type 2 HRS will have refractory ascites as the leading problem. Prompt diagnosis of type 1 HRS can halt the progression of HRS to acute tubular necrosis if the combined treatment of albumin infusion and vasoconstrictors is started timely. HRS reversal was seen in 34%-60% of patients, followed with decreasing mortality. Baseline serum levels of creatinine less than 5 mg/dL, bilirubin less than 10 mg/dL, and increased mean arterial pressure of over 5 mmHg by day 3 of the combined treatment of vasoconstrictor and albumin are the predictors of good response. Type 1 HRS can be prevented in some conditions such as albumin infusion in SBP, prophylactic antibiotics for upper gastrointestinal hemorrhage, albumin replacement after large volume paracentesis in cirrhotic patients with massive ascites. The benefit of albumin infusion in infection with primary source other than SBP requires more studies.

Entities:  

Keywords:  Acute kidney injury; Albumin; Cirrhosis; Hepatorenal syndrome; Vasoconstrictor

Year:  2015        PMID: 26261732      PMCID: PMC4526839          DOI: 10.4292/wjgpt.v6.i3.28

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  29 in total

Review 1.  Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.

Authors:  Lise L Gluud; Kurt Christensen; Erik Christensen; Aleksander Krag
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

2.  Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis.

Authors:  Francesco Salerno; Valentina Monti
Journal:  Hepatology       Date:  2014-02-28       Impact factor: 17.425

Review 3.  Terlipressin for hepatorenal syndrome.

Authors:  Lise Lotte Gluud; Kurt Christensen; Erik Christensen; Aleksander Krag
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

4.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Authors:  P Sort; M Navasa; V Arroyo; X Aldeguer; R Planas; L Ruiz-del-Arbol; L Castells; V Vargas; G Soriano; M Guevara; P Ginès; J Rodés
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

5.  Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.

Authors:  Juan Carlos Q Velez; Paul J Nietert
Journal:  Am J Kidney Dis       Date:  2011-09-29       Impact factor: 8.860

Review 6.  Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis.

Authors:  Mirela Dobre; Sevag Demirjian; Ashwini R Sehgal; Sankar D Navaneethan
Journal:  Int Urol Nephrol       Date:  2010-03-20       Impact factor: 2.370

Review 7.  Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction.

Authors:  J A Leithead; P C Hayes; J W Ferguson
Journal:  Aliment Pharmacol Ther       Date:  2014-02-13       Impact factor: 8.171

Review 8.  Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.

Authors:  Sashidhar V Sagi; Sahil Mittal; Krishna S Kasturi; Gagan K Sood
Journal:  J Gastroenterol Hepatol       Date:  2010-01-14       Impact factor: 4.029

9.  Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis.

Authors:  A Luca; J C García-Pagán; J Bosch; F Feu; W Jiménez; A Ginés; M Fernández; A Escorsell; V Arroyo; J Rodés
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.